Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134884 · ClinicalTrials.gov registry record · Phase 1
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
A Phase 1 study, sponsored by Kathy Miller.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04134884 is a Phase 1 study that has completed, run by Kathy Miller. The registered enrollment target is 34 participants.
The verdict
NCT04134884, a Phase 1 study, has completed, sponsored by Kathy Miller.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer
Interventions
- DRUG Talazoparib
- DRUG ASTX727
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2024-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134884
The ClinicalTrials.gov registry entry for NCT04134884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT04134884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04134884 about?
NCT04134884 is a clinical study titled "Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer". This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer
What is the current status of trial NCT04134884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-04-01. Estimated completion is 2024-03-14.
What interventions are being tested in trial NCT04134884?
The interventions under investigation include: Talazoparib (DRUG), ASTX727 (DRUG).
Who is sponsoring clinical trial NCT04134884?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.